Chen Tingting, Yang Yanling, Han Haonan, Liu Dongmin, Yuan Yajing, Xu Liming
Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China.
Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, College of Basic Medical Sciences, China Three Gorges University, Yichang 443002, China.
Zhongguo Fei Ai Za Zhi. 2025 May 20;28(5):353-362. doi: 10.3779/j.issn.1009-3419.2025.102.20.
Small cell lung cancer (SCLC) is the thoracic malignant tumor and accounts for about 15% of lung malignancies and transfer often occurs by the time of diagnosis. Extensive stage-small cell lung cancer (ES-SCLC) accounts for about 2/3 of all SCLC. For many years, radiotherapy has occupied an important position in the treatment of SCLC, especially in the treatment of ES-SCLC, because SCLC is more sensitive to radiotherapy. However, in recent years, immune checkpoint inhibitor has shown more excellent antitumor activity in the treatment of ES-SCLC and become the mainstream argument for the treatment of ES-SCLC. However, will radiotherapy be buried by the times among the therapeutic approaches for ES-SCLC? In this article, we will review the clinical progress of radiotherapy, immunotherapy and combination therapy for ES-SCLC. .
小细胞肺癌（SCLC）是一种胸部恶性肿瘤，约占肺部恶性肿瘤的15%，且在诊断时常常已经发生转移。广泛期小细胞肺癌（ES-SCLC）约占所有SCLC的2/3。多年来，放射治疗在SCLC的治疗中占据重要地位，尤其是在ES-SCLC的治疗中，因为SCLC对放疗更为敏感。然而，近年来，免疫检查点抑制剂在ES-SCLC的治疗中显示出更优异的抗肿瘤活性，并成为ES-SCLC治疗的主流观点。那么，在ES-SCLC的治疗方法中，放射治疗会被时代所埋没吗？在本文中，我们将综述ES-SCLC的放疗、免疫治疗及联合治疗的临床进展。
